MedTrace Logo

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

NCT01891968 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-04-23

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if bortezomib can help to control MDS. The safety of this drug will also be studied.

Bortezomib is designed to block a protein that causes cells to grow. This may cause cancer cells to die.

Conditions

Interventions

DRUG

Bortezomib

1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Guillermo Garcia-Manero, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-07
Primary Completion
2017-01-18
Completion
2017-01-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01891968 on ClinicalTrials.gov